Corvus Pharmaceuticals Inc Stock
Corvus Pharmaceuticals Inc shows a slight decrease today, losing -€0.020 (-0.270%) compared to yesterday.
Corvus Pharmaceuticals Inc is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
With a target price of 10 € there is a positive potential of 33.69% for Corvus Pharmaceuticals Inc compared to the current price of 7.48 €.
Our community identified positive and negative aspects for Corvus Pharmaceuticals Inc stock for the coming years. 0 users see the criterium "Brand" as a plus for the Corvus Pharmaceuticals Inc stock. On the other hand our users think that "Brand" could be a problem in the future.
Pros and Cons of Corvus Pharmaceuticals Inc in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
B****
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corvus Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | -0.270% | -2.975% | 15.920% | -1.704% | 54.321% | 685.423% | 130.061% |
| Ardelyx Inc. | -1.150% | 4.938% | 4.547% | -6.506% | 1.873% | 194.138% | -2.880% |
| Krystal Biotech | 0.800% | 8.522% | 17.592% | 14.742% | 32.194% | 183.380% | - |
| Evolus Inc | 0.880% | -1.724% | -5.785% | -51.695% | -45.714% | -12.977% | 91.019% |
Comments
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target lowered by analysts at Mizuho from $12.00 to $11.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $17.00 price target on the stock, up previously from $15.00.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
Show more
Ratings data for CRVS provided by MarketBeat
News
Corvus (CRVS) Q2 Loss Beats Estimates
Corvus Pharmaceuticals (NASDAQ:CRVS), a clinical-stage biopharmaceutical company focused on developing immunology and oncology therapies, released its earnings results for Q2 2025 on August 7, 2025
